Galapagos : Des ambitions affichées qui devront être démontrées
Nous initions la couverture de Galapagos avec une recommandation à Neutre et un OC de 44 €. Contrairement à beaucoup de ses comparables du secteur biotech, Galapagos présente une trésorerie solide du fait de son accord avec Gilead et d’un médicament déjà sur le marché : Jyseleca. En revanche, le stade de développement actuel du pipeline et son évolution stratégique en oncologie justifient notre prudence. Les POS appliquées à sa plateforme CAR-T « au lit du patient » ne pourront s...Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.